71_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Shareholder_NN Information_NN The_DT share_NN price_NN is_VBZ obtainable_JJ from_IN the_DT following_NN :_: US_NNP Depositary_NNP Financial_NNP Times_NNP ,_, Daily_NNP Telegraph_NNP ,_, The_DT Independent_NNP ,_, The_NNP Bank_NNP of_IN New_NNP York_NNP Cambridge_NNP Evening_NNP News_NNP ,_, The_DT Guardian_NNP ,_, Daily_NNP Express_NNP ._.
Investor_NNP Relations_NNP PO_NNP Box_NNP 11258_CD London_NNP Stock_NNP Exchange_NNP Church_NNP Street_NNP Station_NNP mnemonic_JJ CAT_NNP New_NNP York_NNP ,_, NY10286-1258_NNP ,_, US_NNP NASDAQ_NNP Investor_NNP relations_NNS Information_NN on_IN CAT_NNP is_VBZ available_JJ online_NN via_IN the_DT internet_NN at_IN mnemonic_JJ CATG_NNP www_NN ._.
com_NN Announcements_NNP Security_NNP analysts_NNS and_CC investment_NN professionals_NNS should_MD direct_VB their_PRP$ First_JJ quarter_NN mid_VBD February_NNP enquiries_NNS in_IN the_DT first_JJ instance_NN to_TO :_: Interim_NNP mid_VBD May_NNP UK_NNP Europe_NNP Third_NNP quarter_NN early_JJ September_NNP Final_NNP mid_VBD November_NNP Corporate_NNP Communications_NNPS Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Shareholders_NNS Milstein_NNP Building_NNP There_EX are_VBP approximately_RB 2,300_CD registered_VBN shareholders_NNS ._.
Granta_NNP Park_NNP Cambridge_NNP CB1_NNP 6GH_NNP ,_, UK_NNP Company_NNP Secretary_NNP and_CC registered_VBN office_NN US_NNP Diane_NNP Mellett_NNP LLB_NNP JD_NNP Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN The_DT Trout_NNP Group_NNP LLC_NNP Milstein_NNP Building_NNP 740_NNP Broadway_NNP ,_, Suite_NNP 903_CD Granta_NNP Park_NNP New_NNP York_NNP ,_, NY10003_NNP ,_, US_NNP Cambridge_NNP CB1_NNP 6GH_NNP ,_, UK_NNP Registered_NNP number_NN 3234033_CD Registrars_NNPS Computershare_NNP Investor_NNP Services_NNP PLC_NNP PO_NNP Box_NNP 82_CD The_DT Pavilions_NNP Bridgwater_NNP Road_NNP Bristol_NNP BS99_NNP 7NH_NNP ,_, UK_NNP Tel_NNP 0870 702 0000_CD PFIC_NNP Annual_JJ Information_NN Statement_NNP Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN The_DT following_VBG information_NN applies_VBZ to_TO United_NNP States_NNPS shareholders_NNS only_RB ._.
For_IN the_DT year_NN ended_VBD 30_CD September_NNP 2002_CD ,_, we_PRP believe_VBP that_IN the_DT Company_NN was_VBD not_RB a_DT Passive_NNP Foreign_NNP Investment_NNP Corporation_NNP PFIC_NNP as_IN defined_VBN by_IN Section_NN 1297_CD of_IN the_DT United_NNP States_NNP Code_NNP ._.
This_DT conclusion_NN is_VBZ a_DT factual_JJ determination_NN that_WDT is_VBZ made_VBN annually_RB and_CC therefore_RB may_MD be_VB subject_JJ to_TO change_VB in_IN the_DT future_NN ._.
As_IN the_DT Company_NN was_VBD at_IN one_CD time_NN a_DT PFIC_NNP we_PRP provide_VBP the_DT following_VBG information_NN ._.
Fiscal_JJ year_NN ended_VBD 30_CD September_NNP 2002_CD 1_CD This_DT information_NN is_VBZ being_VBG provided_VBN pursuant_JJ to_TO Section_NNP 1.1295-1T_NNP of_IN the_DT United_NNP States_NNPS Treasury_NNP Regulations_NNPS ._.
2_CD This_DT PFIC_NNP Annual_JJ Information_NN Statement_NN applies_VBZ to_TO the_DT financial_JJ year_NN of_IN the_DT Company_NN beginning_VBG 1_CD October_NNP 2001_CD and_CC ending_VBG 30_CD September_NNP 2002_CD ._.
3_CD The_DT Company_NN had_VBD negative_JJ ordinary_JJ earnings_NNS and_CC no_DT net_JJ capital_NN gain_NN for_IN the_DT taxable_JJ year_NN indicated_VBD above_IN ._.
4_CD During_IN the_DT year_NN no_DT actual_JJ or_CC deemed_VBD distributions_NNS were_VBD made_VBN ._.
5_CD The_DT Company_NN has_VBZ given_VBN the_DT information_NN set_VBN forth_RB in_IN paragraphs_NNS 14_CD above_IN to_TO enable_VB the_DT shareholder_NN to_TO establish_VB that_IN the_DT Companys_NNP ordinary_JJ earnings_NNS and_CC net_JJ capital_NN gain_NN are_VBP computed_VBN in_IN accordance_NN with_IN US_NNP income_NN tax_NN principles_NNS and_CC to_TO determine_VB the_DT shareholders_NNS pro_JJ rata_JJ share_NN thereof_RB ._.
72_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Glossary_NNP Please_UH use_VB this_DT glossary_NN of_IN terms_NNS to_TO give_VB you_PRP a_DT better_JJR understanding_NN of_IN our_PRP$ business_NN ._.
Acute_JJ Respiratory_NNP Distress_NNP Syndrome_NNP ARDS_NNP A_NNP severe_JJ form_NN of_IN acute_JJ failure_NN Nasal_NNP patency_NN The_DT openness_NN of_IN airways_NNS in_IN the_DT nose_NN ._.
of_IN lung_NN function_NN which_WDT can_MD occur_VB after_IN trauma_NN ,_, sepsis_NN or_CC inhalation_NN of_IN a_DT toxic_JJ substance_NN ._.
Ocular_JJ Of_IN ,_, or_CC relating_VBG to_TO ,_, the_DT eye_NN ._.
A_DT negotiable_JJ US_NNP certificate_NN representing_VBG ownership_NN Orphan_NNP Drug_NNP status_NN Denotes_VBZ a_DT drug_NN for_IN a_DT rare_JJ disease_NN less_RBR than_IN 5_CD per_IN 10,000_CD of_IN shares_NNS in_IN a_DT non-US_JJ corporation_NN ,_, ADRs_NNS are_VBP quoted_VBN and_CC traded_VBN in_IN US_NNP dollars_NNS on_IN US_NNP population_NN in_IN Europe_NNP ._.
Orphan_JJ designation_NN brings_VBZ commercial_JJ benefits_NNS to_TO the_DT company_NN securities_NNS markets_NNS ._.
CATs_NNS ADRs_NNS are_VBP quoted_VBN on_IN the_DT NASDAQ_NNP National_NNP Market_NNP and_CC one_CD developing_VBG the_DT drug_NN ._.
CAT_NNP ADR_NNP represents_VBZ one_CD ordinary_JJ share_NN in_IN CAT_NNP ._.
Phakotrabeclectomy_NNP Combined_NNP surgery_NN to_TO simultaneously_RB treat_VB glaucoma_NN Agonistic_NNP A_NNP positive_JJ response_NN induced_VBN by_IN the_DT binding_JJ of_IN a_DT target_NN molecule_NN to_TO a_DT cell_NN and_CC a_DT cataract_NN ._.
Phage_NNP Abbreviation_NNP for_IN bacteriophage_NN ,_, a_DT filamentous_JJ virus_NN that_WDT infects_VBZ bacteria_NNS ._.
Allergic_JJ disease_NN disorder_NN Conditions_NNS caused_VBN by_IN an_DT overreaction_NN of_IN the_DT immune_JJ system_NN to_TO foreign_JJ substances_NNS which_WDT are_VBP usually_RB considered_VBN to_TO be_VB harmless_JJ ._.
Phage_NNP display_NN CATs_NNS proprietary_JJ technology_NN in_IN which_WDT antibodies_NNS are_VBP displayed_VBN on_IN the_DT tip_NN of_IN a_DT phage_JJ virus_NN ._.
Pharmacokinetics_NNP The_NNP study_NN of_IN the_DT time_NN course_NN of_IN a_DT drug_NN in_IN the_DT body_NN following_VBG Antibody_NNP A_NNP protein_NN produced_VBN by_IN B-lymphocytes_NNS white_JJ blood_NN cells_NNS of_IN the_DT immune_JJ administration_NN ._.
system_NN ,_, which_WDT specifically_RB recognizes_VBZ a_DT target_NN molecule_NN known_VBN as_IN an_DT antigen_NN ._.
Phase_NN I_PRP clinical_JJ trial_NN A_DT first_JJ in_IN man_NN study_NN conducted_VBN to_TO determine_VB the_DT biological_JJ Antigen_NNP A_NNP molecule_NN recognized_VBN by_IN an_DT antibody_NN ._.
effects_NNS of_IN a_DT drug_NN ,_, especially_RB its_PRP$ safety_NN ,_, tolerability_NN and_CC pharmacokinetics_NNS ._.
Autoimmune_JJ disease_NN disorder_NN Conditions_NNS which_WDT occur_VBP when_WRB the_DT human_JJ immune_JJ Phase_NN I_PRP II_NNP clinical_JJ trial_NN Early_RB study_NN in_IN patients_NNS with_IN the_DT disease_NN for_IN which_WDT the_DT product_NN system_NN reacts_VBZ against_IN a_DT component_NN of_IN the_DT human_JJ body_NN ._.
candidate_NN is_VBZ being_VBG developed_VBN to_TO determine_VB safety_NN and_CC preliminary_JJ efficacy_NN ._.
B-Lymphocyte_JJ stimulator_NN BLyS_NNP A_NNP protein_NN which_WDT stimulates_VBZ B-lymphocytes_NNS to_TO Phase_NN III_NNP clinical_JJ trial_NN Trials_NNS with_IN larger_JJR patient_NN numbers_NNS to_TO confirm_VB a_DT drugs_NNS efficacy_NN produce_VBP antibodies_NNS ._.
This_DT is_VBZ the_DT last_JJ phase_NN of_IN trials_NNS prior_RB to_TO filing_VBG for_IN market_NN approval_NN ._.
Cirrhosis_NNP A_NNP condition_NN of_IN chronic_JJ scarring_NN of_IN the_DT liver_NN ,_, characterised_VBN by_IN the_DT presence_NN Pulmonary_NNP Relating_VBG to_TO the_DT lung_NN ._.
of_IN fibrous_JJ tissue_NN ,_, which_WDT destroys_VBZ the_DT liver_NN architecture_NN and_CC interferes_VBZ with_IN normal_JJ liver_NN function_NN ._.
Rheumatoid_JJ arthritis_NNS A_DT condition_NN characterised_VBN by_IN chronic_JJ inflammation_NN and_CC gradual_JJ destruction_NN of_IN the_DT joints_NNS ._.
Crohns_NNS disease_NN A_DT chronic_JJ inflammatory_JJ disorder_NN of_IN the_DT bowels_NNS ._.
Scleroderma_NNP An_DT autoimmune_JJ disease_NN of_IN the_DT connective_JJ tissues_NNS which_WDT affects_VBZ blood_NN Cytokines_NNP Small_NNP protein_NN molecules_NNS that_WDT are_VBP released_VBN by_IN cells_NNS which_WDT affect_VBP the_DT vessels_NNS and_CC is_VBZ characterised_VBN by_IN thickening_VBG of_IN the_DT skin_NN and_CC fibrosis_NN of_IN the_DT internal_JJ organs_NNS behavior_NN of_IN other_JJ cells_NNS and_CC regulate_VB biological_JJ processes_NNS ._.
TM_NNP D2E7_NNP Original_NNP codename_NN for_IN Humira_NNP adalimumab_NN ._.
Systemic_JJ lupus_NN erythematosus_VBZ SLE_NNP Often_RB known_VBN as_IN lupus_NN ,_, one_CD of_IN a_DT group_NN of_IN Diabetic_NNP nephropathy_NN Chronic_NNP kidney_NN disease_NN ,_, characterised_VBN by_IN the_DT leaking_VBG of_IN severe_JJ autoimmune_JJ diseases_NNS characterised_VBN by_IN the_DT production_NN of_IN auto_NN antibodies_NNS which_WDT protein_NN into_IN the_DT urine_NN ,_, which_WDT occurs_VBZ as_IN a_DT result_NN of_IN long-standing_JJ diabetes_NN ._.
can_MD damage_VB internal_JJ organs_NNS such_JJ as_IN the_DT kidney_NN ._.
Efficacy_NNP The_NNP measure_NN of_IN the_DT effectiveness_NN of_IN a_DT drug_NN in_IN treating_VBG a_DT particular_JJ condition_NN ._.
TGF_NNP Transforming_VBG growth_NN factor_NN beta_JJ TGF_NNP is_VBZ a_DT family_NN of_IN multifunctional_JJ biological_JJ molecules_NNS ,_, excess_JJ production_NN of_IN which_WDT is_VBZ associated_VBN with_IN fibrosis_NN and_CC scarring_NN ._.
Eosinophil_NNP A_NNP type_NN of_IN white_JJ blood_NN cell_NN ,_, containing_VBG eosinophilic_JJ granules_NNS ,_, which_WDT are_VBP particularly_RB involved_VBN in_IN allergic_JJ disorders_NNS ._.
TGF_NNP The_NNP form_NN of_IN TGF_NNP that_WDT is_VBZ strongly_RB linked_VBN to_TO fibrosis_NN and_CC scarring_NN of_IN the_DT skin_NN as_IN 1_CD well_RB as_IN most_JJS internal_JJ organs_NNS ._.
Eotaxin_NNP A_NNP protein_NN that_WDT attracts_VBZ eosinophils_NNS into_IN tissues_NNS ,_, where_WRB they_PRP can_MD degranulate_VB and_CC cause_VB tissue_NN damage_NN ._.
TGF_NNP The_NNP form_NN of_IN TGF_NNP that_WDT is_VBZ strongly_RB associated_VBN with_IN scarring_VBG in_IN and_CC around_IN 2_CD the_DT eye_NN ._.
Fibrosis_NNP A_NNP pathological_JJ process_NN characterised_VBN by_IN the_DT proliferation_NN of_IN fibrous_JJ connective_JJ tissue_NN ,_, the_DT main_JJ component_NN of_IN scar_NN tissue_NN ,_, which_WDT may_MD occur_VB as_IN a_DT result_NN of_IN repeated_VBN TNF_NNP Tumour_NNP necrosis_NN factor_NN alpha_NN TNF_NNP belongs_VBZ to_TO the_DT cytokine_NN family_NN of_IN injury_NN to_TO a_DT tissue_NN ._.
It_PRP has_VBZ pro-inflammatory_JJ effects_NNS and_CC when_WRB produced_VBN excessively_RB is_VBZ responsible_JJ for_IN increasing_VBG tissue_NN damage_NN in_IN disorders_NNS such_JJ as_IN rheumatoid_JJ arthritis_NNS ._.
Glaucoma_NNP A_NNP group_NN of_IN eye_NN conditions_NNS in_IN which_WDT the_DT optic_JJ nerve_NN is_VBZ permanently_RB damaged_VBN at_IN the_DT point_NN where_WRB it_PRP leaves_VBZ the_DT eye_NN ,_, resulting_VBG in_IN significant_JJ loss_NN of_IN vision_NN or_CC blindness_NN ._.
Topical_JJ medication_NN Medication_NNP applied_VBD to_TO the_DT surface_NN as_IN opposed_VBN to_TO injection_NN The_DT major_JJ cause_NN of_IN the_DT damage_NN is_VBZ thought_VBN to_TO be_VB raised_VBN pressure_NN inside_IN the_DT eye_NN ._.
Glioma_NNP A_NNP type_NN of_IN malignant_JJ brain_NN tumor_NN ._.
Trabeculectomy_NNP The_NNP commonest_JJS type_NN of_IN surgical_JJ operation_NN performed_VBN on_IN patients_NNS with_IN glaucoma_NN to_TO lower_JJR intraocular_JJ pressure_NN ._.
Haematopoietic_NNP Relating_VBG to_TO stem_VB cells_NNS from_IN which_WDT all_DT blood_NN cells_NNS are_VBP derived_VBN ._.
TRAIL-R1_CD R2_NNP Proteins_NNPS expressed_VBD on_IN the_DT surface_NN of_IN a_DT number_NN of_IN cancer_NN cells_NNS which_WDT ,_, TM_NNP Humira_NNP D2E7_NNP A_NNP human_JJ monoclonal_NN anti-TNF_JJ antibody_NN developed_VBD for_IN the_DT when_WRB triggered_VBN ,_, induce_VB programmed_JJ cell_NN death_NN apoptosis_NN ._.
Lymphocyte_NNP A_NNP type_NN of_IN white_JJ blood_NN cell_NN ._.
A_DT sub-class_JJ known_VBN as_IN B-lymphocytes_NNS produce_VBP antibodies_NNS ._.
Mast_NNP cells_NNS Tissue_NNP based_VBN cells_NNS important_JJ in_IN allergic_JJ and_CC inflammatory_JJ reactions_NNS ._.
Microarray_NNP A_NNP flat_JJ ,_, solid_JJ support_NN with_IN a_DT large_JJ number_NN of_IN ordered_VBN ,_, densely_RB packed_JJ molecules_NNS ,_, usually_RB protein_NN or_CC DNA_NN ,_, arranged_VBN on_IN its_PRP$ surface_NN ._.
Monoclonal_NNP antibody_NN An_DT antibody_NN derived_VBN from_IN clones_NNS of_IN a_DT single_JJ cell_NN :_: all_DT molecules_NNS have_VBP identical_JJ antigen_NN binding_JJ sites_NNS ._.
Highlights_NNS of_IN the_DT Year_NN Chairmans_NNPS Statement_NNP 02_CD Abbott_NNP made_VBD regulatory_JJ submissions_NNS in_IN the_DT US_NNP and_CC Europe_NNP for_IN marketing_NN approval_NN of_IN Clinical_JJ and_CC Pre-Clinical_JJ Pipeline_NNP 04_CD Introduction_NN from_IN the_DT Chief_NNP Executive_NNP Officer_NNP 05_CD Humira_NNP D2E7_NNP ,_, a_DT human_JJ monoclonal_JJ antibody_NN anti-TNF_JJ therapy_NN for_IN rheumatoid_JJ Review_NNP of_IN the_DT Year_NN 06_CD arthritis_NN ,_, isolated_VBN and_CC optimised_VBN by_IN CAT_NNP in_IN collaboration_NN with_IN Abbott_NNP ._.
Financial_NNP Review_NNP 18_CD Board_NNP of_IN Directors_NNS 26_CD CAT-152_NN ,_, a_DT human_JJ monoclonal_JJ antibody_NN against_IN TGF_NNP used_VBD as_IN an_DT anti-scarring_JJ agent_NN after_IN 2_CD Senior_JJ Executives_NNS 28_CD surgery_NN to_TO treat_VB glaucoma_NN ,_, produced_VBD encouraging_JJ Phase_NN II_NNP clinical_JJ trial_NN results_NNS and_CC Scientific_NNP Advisory_NNP Board_NNP 28_CD commenced_VBD pivotal_JJ International_NNP Phase_NN III_NNP clinical_JJ trials_NNS ._.
Financial_NNP Statements_NNP 29_CD Directors_NNS Report_NNP 30_CD Orphan_NNP Drug_NNP status_NN awarded_VBN for_IN CAT-192_NNP ,_, the_DT human_JJ anti-TGF_JJ monoclonal_JJ antibody_NN 1_CD Remuneration_NNP Report_NNP 32_CD being_VBG developed_VBN with_IN Genzyme_NNP as_IN a_DT potential_JJ drug_NN to_TO treat_VB scleroderma_NN ._.
Corporate_JJ Governance_NNP 36_CD Independent_NNP Auditors_NNS Report_NNP 39_CD CAT-213_NN ,_, a_DT human_JJ anti-eotaxin_JJ monoclonal_JJ antibody_NN shows_VBZ encouraging_JJ results_NNS in_IN a_DT 1_CD Consolidated_NNP Profit_NN and_CC Loss_NN Account_NNP 40_CD Phase_NN I_PRP II_NNP trial_NN as_IN a_DT potential_JJ treatment_NN for_IN allergic_JJ disorders_NNS ._.
Consolidated_NNP Statement_NNP of_IN Total_NNP Recognised_NNP Gains_NNS and_CC Losses_NNS 40_CD TRAIL-R1_CD mAb_NNP ,_, a_DT potential_JJ anti-cancer_JJ treatment_NN ,_, entered_VBD a_DT Phase_NN I_PRP clinical_JJ trial_NN conducted_VBN Consolidated_NNP Balance_NNP Sheet_NNP 41_CD Company_NN Balance_NNP Sheet_NNP 42_CD by_IN CATs_NNS partner_NN ,_, HGSI_NNP ._.
Consolidated_NNP Cash_NNP Flow_NNP Statement_NNP 43_CD Five_CD exclusive_JJ therapeutic_JJ licences_NNS granted_VBN :_: to_TO HGSI_NNP three_CD ,_, Amgen_NNP and_CC Wyeth_NNP Research_NNP for_IN Notes_NNP to_TO the_DT Financial_NNP Statements_NNP 44_CD Selected_NNP Financial_NNP Data_NNP 69_CD developing_VBG CAT-derived_JJ antibodies_NNS against_IN a_DT range_NN of_IN disease-associated_JJ molecular_JJ targets_NNS ._.
Corporate_JJ Advisors_NNP 70_CD Shareholder_NN Information_NN 71_CD Co-development_NN collaboration_NN signed_VBN with_IN Amrad_NNP ._.
Glossary_NNP 72_CD Research_NNP alliance_NN signed_VBN with_IN Chugai_NNP ,_, a_DT leading_VBG Japanese_JJ pharmaceutical_JJ company_NN and_CC ,_, since_IN year_NN end_NN ,_, a_DT second_JJ agreement_NN with_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP ._.
Royalty_NN obligations_NNS to_TO Drug_NNP Royalty_NNP Corporation_NNP bought_VBD back_RB ._.
Peter_NNP Chambr_NNP appointed_VBN as_IN new_JJ CEO_NNP ._.
Design_NN and_CC produced_VBN by_IN Radley_NNP Yeldar_NNP Photography_NNP by_IN George_NNP Brooks_NNP and_CC John_NNP Edwards_NNP Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Annual_JJ Report_NNP 2002_CD Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Cambridge_NNP Antibody_NNP Technology_NNP Group_NNP plc_NN Milstein_NNP Building_NNP ,_, Granta_NNP Park_NNP ,_, Cambridge_NNP ,_, CB1_NNP 6GH_NNP ,_, UK_NNP Annual_JJ Report_NNP Telephone_NNP :_: 44_CD 0_CD 1223 471 471_CD Fax_NNP :_: 44_CD 0_CD 1223 471 472_CD E-mail_NN :_: info@cambridgeantibody_NN ._.
